
Personal Genome Diagnostics (PGDx) develops comprehensive genomic profiling solutions for oncology, enabling clinicians and labs to rapidly detect actionable genomic alterations in solid tumors and liquid biopsies. Founded in 2010 by Johns Hopkins researchers, PGDx's elio portfolio includes tissue and plasma CGP solutions used in laboratories worldwide to close the precision oncology gap.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account